Peptide Research Glossary

The individual chemical units that link together to form peptides and proteins. Twenty standard amino acids make up most human biology.

The fraction of a dose that actually reaches circulation in active form. Most peptides have near-zero oral bioavailability, which is why they are injected.

The time it takes for half a dose to clear the body. Engineered peptides often extend a natural hormone’s short half-life into days.

Injected into muscle, which is more vascular than fat and can change how fast a compound is absorbed. Chosen over SubQ for specific drugs and volumes.

Using doses well below the studied therapeutic range. For GLP-1 drugs this is mostly anecdote-driven, without trial data to support it.

Delivery by mouth. It is convenient but hard for peptides, which the gut digests; only a few (like oral semaglutide) survive with special formulation.

A short chain of amino acids — the same building blocks as proteins, just fewer of them. The body produces thousands as signaling molecules.

Combining multiple peptides at once. It is common in unregulated use but multiplies the unknowns, since interactions are rarely studied.

How much of a compound is needed to produce a given effect. A more potent peptide achieves the same result at a lower dose.

A long, folded chain of amino acids. The line between a peptide and a protein is fuzzy, but proteins are generally larger and structurally complex.

A protein on or inside a cell that detects a specific molecule and triggers a response. Peptides act by binding these docking sites.

A molecule that binds a receptor and activates it, mimicking the body’s natural signal. Most therapeutic peptides work this way.

A molecule that binds a receptor but blocks it rather than activating it, dampening a natural signal instead of mimicking it.

When a receptor becomes less responsive after sustained stimulation, so the same dose produces a smaller effect over time.

Mixing a freeze-dried (lyophilized) peptide with a sterile diluent before use. Correct technique and storage protect the peptide’s stability and potency.

A compound that prompts the body to release more of its own hormone, rather than supplying the hormone directly.

The chain of events that turns a signal at a receptor into a change inside the cell. It explains how a tiny peptide dose produces large downstream effects.

Injected into the fat layer just under the skin — the most common route for peptide therapeutics.

Gradually increasing a dose over weeks to let the body adapt and to limit side effects. Standard practice for GLP-1 drugs.

A diminishing response to a fixed dose over time, often driven by receptor desensitization. Whether it meaningfully affects GLP-1 drugs is debated.

An experimental fat-targeting peptide that showed serious toxicity in animals — a cautionary example of a mechanism that did not translate safely.

A pancreatic hormone co-released with insulin that promotes fullness and slows gastric emptying. Amylin agonists are a next wave of weight-loss candidates.

A growth-hormone fragment once marketed for fat loss that failed to show meaningful benefit in controlled human trials.

An investigational combination of an amylin analog (cagrilintide) and semaglutide being studied for greater weight loss than either alone.

The intrusive, near-constant thoughts about food that many people report quieting on GLP-1 drugs — a window into the biology of appetite.

The rate at which the stomach passes food to the intestine. GLP-1 drugs slow it, which increases fullness but can also cause nausea.

Markedly delayed stomach emptying that can cause persistent nausea and bloating — a recognized concern with GLP-1 therapy in some people.

A second incretin hormone targeted alongside GLP-1 in newer dual-agonist therapies.

A gut hormone released after eating that curbs appetite, slows gastric emptying, and improves insulin response.

A pancreatic hormone that raises blood sugar and increases energy expenditure. Newer multi-agonist drugs deliberately engage its receptor.

A gut hormone (chiefly GLP-1 and GIP) released with food that amplifies insulin release. The incretin effect is the foundation of modern metabolic peptides.

The muscle lost alongside fat during rapid weight loss. Protecting lean mass with protein and resistance training is a key concern on GLP-1 drugs.

An earlier once-daily GLP-1 receptor agonist that established the class for diabetes and weight management before longer-acting successors arrived.

A form of fatty liver disease with inflammation and scarring, formerly called NASH. Several metabolic peptides are being tested against it.

An investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, with striking early weight-loss data but not yet approved.

A long-acting GLP-1 receptor agonist with extensive human trials for weight loss, glycemic control, and cardiovascular outcomes.

An investigational GLP-1/glucagon dual agonist studied for obesity and fatty liver disease, still working through clinical trials.

An experimental appetite-suppressing small molecule (not a peptide) with promising weight-loss signals but unresolved safety questions.

A dual GIP/GLP-1 receptor agonist showing large weight-loss and metabolic effects in randomized trials.

The tendency to regain weight after stopping a GLP-1 drug, since the underlying appetite biology returns. Trials consistently show substantial rebound.

The point where weight loss stalls as the body adapts its metabolism and appetite. A predictable, well-documented phase of treatment.

A long-acting GHRH analog used to raise growth-hormone levels, often paired with ipamorelin. Human outcome data are limited.

A protein that blocks myostatin, a brake on muscle growth. The muscle-building promise is largely preclinical and its therapeutic use is unproven.

A growth-hormone-releasing peptide similar to GHRP-6 with somewhat less appetite stimulation. Human evidence remains thin.

An early growth-hormone-releasing peptide known for strongly stimulating appetite. Largely superseded by more selective secretagogues.

A peptide that stimulates the body’s own growth-hormone release rather than supplying synthetic hGH. The rationale is a more natural, pulsatile pattern.

An older, potent growth-hormone-releasing peptide that tends to desensitize quickly with use, which limited its practical appeal.

The hormone through which much of growth hormone’s effect is actually delivered. It drives tissue growth but is also implicated in aging pathways.

A selective growth-hormone-releasing peptide valued for a cleaner side-effect profile than older secretagogues. Rigorous human evidence is sparse.

A peptide that acts as a master regulator of reproductive hormones, drawing research interest for fertility and sexual-health applications.

A melanocortin agonist marketed for tanning that carries real safety concerns, including effects on blood pressure and moles.

A melanocortin agonist approved for certain cases of low sexual desire, acting on the brain rather than on blood flow.

A growth-hormone-releasing hormone (GHRH) analog that prompts the pituitary to release growth hormone. It has a long clinical history but modest evidence for anti-aging claims.

A GHRH analog and one of the few growth-hormone peptides with genuine FDA approval, indicated for HIV-associated visceral fat.

The formation of new blood vessels. Improved blood supply is a proposed mechanism behind several repair peptides’ claimed healing effects.

A synthetic peptide with promising rodent data for tendon and gut healing, but essentially no controlled human trials.

Hydrolyzed collagen taken orally — one of the few peptide supplements with reasonable human data for skin and connective-tissue support.

A copper-binding peptide studied for skin and wound applications, with more topical than systemic evidence.

A human antimicrobial peptide central to innate immunity. Interest in it for infection and healing is largely mechanistic, with thin human outcome data.

Studied preclinically for tissue repair and angiogenesis; human evidence is minimal.

The slow process by which tendon tissue rebuilds under load. Its limited blood supply is why tendons heal differently and slowly.

An immune-modulating peptide used clinically in some countries as an adjunct in infections and certain cancers, with a genuine evidence base in those settings.

A naturally occurring peptide involved in cell migration and wound repair. Its regenerative promise rests mostly on preclinical data.

The brain’s resilience against age-related decline, built through education, mental engagement, and social activity. It buffers the impact of aging pathology.

A naturally occurring peptide named for its association with deep sleep, though evidence that supplementing it improves sleep is weak.

An amino acid found in tea associated with calm alertness and modestly better sleep quality in some studies.

A synthetic peptide studied mainly in Russia for anxiety and cognition. The available human data are limited and hard to independently verify.

A peptide marketed as a nootropic with claims for focus and neuroprotection that outrun the rigorous human evidence available.

An NNMT-inhibiting compound promoted for metabolism and fat loss, well ahead of the human evidence for those claims.

A cellular energy sensor activated by exercise and fasting that shifts cells toward repair and efficiency — a key longevity signaling hub.

The cell’s recycling process for clearing damaged components. It is a plausible longevity lever, though human benefit is harder to pin down than the mechanism.

Measurable indicators — from blood markers to functional tests — used to estimate biological age and track interventions.

Short peptides marketed as organ-specific “regulators” of aging. The claims rest largely on older, hard-to-replicate research.

Reducing calorie intake without malnutrition. It extends lifespan across many species; the CALERIE trial showed metabolic benefits in humans.

A state in which damaged cells stop dividing but linger and secrete inflammatory signals, contributing to tissue aging.

An estimate of biological age from DNA methylation patterns. A promising research tool, though its use for individual decisions is still maturing.

A synthetic peptide claimed to lengthen telomeres and slow aging. The supporting research is limited and difficult to independently verify.

A plant flavonoid studied as a senolytic. Animal signals are interesting but human evidence is at an early stage.

A simple measure of overall muscle function that reliably predicts mortality and healthy aging in large studies.

A widely used framework organizing the biological processes that drive aging, such as genomic instability, senescence, and mitochondrial dysfunction.

The portion of life spent in good health, free of chronic disease — distinct from total lifespan.

The principle that a mild stress — like exercise, heat, or fasting — triggers adaptations that leave the body more resilient.

A mitochondrial-derived peptide studied for cytoprotective and metabolic effects, promising mechanistically but early in human research.

The chronic, low-grade inflammation that accumulates with age and contributes to many age-related diseases.

A protein whose levels decline with age and correlate with longevity and cognition in studies. Its therapeutic potential remains largely preclinical.

A widely used diabetes drug studied for possible longevity effects. The TAME trial aims to test whether it slows aging in people.

A mitochondrial-derived peptide involved in metabolism and stress response, of research interest for exercise and aging but still preclinical in humans.

A central nutrient-sensing pathway that drives growth. Dialing it down (for example with rapamycin) extends lifespan in animals.

A coenzyme central to energy metabolism; the longevity case rests on strong mechanisms and developing human data.

A precursor the body converts into NAD+. Human data on meaningful longevity benefit are still developing.

An mTOR-inhibiting drug that reliably extends lifespan in animals. Human longevity evidence is promising in mechanism but not yet established.

The age-related loss of muscle mass and strength. Resistance training and adequate protein are the best-supported countermeasures.

Compounds that selectively clear senescent (“zombie”) cells. Animal data are compelling; careful human trials are still early.

A family of NAD+-dependent enzymes tied to stress resistance. The early resveratrol-driven longevity hype has not held up well in humans.

A naturally occurring polyamine that induces autophagy in cells. Observational and early trial data are intriguing but not yet definitive.

A mitochondria-targeting peptide in clinical trials for conditions involving mitochondrial dysfunction, with genuine human studies underway.

An amino acid whose decline with age was linked to aging in animal studies. Whether supplementation extends human healthspan is unproven.

Protective caps on the ends of chromosomes that shorten with cell division. They are a marker of aging but not a simple dial to turn back.

Confining food intake to a set daily window. Evidence supports modest metabolic benefits, though claims sometimes exceed the data.

A gut-derived metabolite that promotes mitophagy (clearing damaged mitochondria), with early human data on muscle and mitochondrial function.

The maximum rate of oxygen use during exercise — one of the strongest modifiable predictors of all-cause mortality.

Sustained low-intensity aerobic exercise that builds mitochondrial and metabolic health — a cornerstone of endurance and longevity programming.

Light movement on rest days to promote blood flow and recovery. Research generally favors it over complete rest for reducing soreness.

The involuntary system balancing “fight-or-flight” (sympathetic) and “rest-and-digest” (parasympathetic) states. Its balance underlies recovery signals like HRV.

Cold plunges and ice baths that can blunt soreness, but may also dampen muscle-building adaptations if used right after strength training.

The primary stress hormone. It is essential in acute doses but, when chronically elevated, impairs sleep, recovery, and tissue repair.

One of the most studied supplements, supporting strength, recovery, and possibly cognition — with a strong safety and evidence record.

A planned reduction in training load for a period to let the body consolidate gains and dissipate accumulated fatigue.

The muscle soreness that peaks a day or two after unfamiliar exercise. It reflects adaptation, not damage that needs to be “fixed.”

The body’s stored form of carbohydrate in muscle and liver. Replenishing it after hard or prolonged exercise is a core part of recovery.

Beat-to-beat variation in heart rate, used as a smoothed signal of recovery and autonomic balance.

A prolonged performance decline from excessive training without adequate recovery. It exists but is over-diagnosed relative to simple under-recovery.

Planned variation in training intensity and volume over time, deliberately building in recovery to drive adaptation and avoid overtraining.

The idea of eating protein around workouts to aid recovery. Total daily protein matters most; the narrow “anabolic window” is smaller than once believed.

Heart rate at complete rest. A rising baseline over several days often signals incomplete recovery or oncoming illness.

Deliberate heat exposure linked in Finnish cohort studies to cardiovascular and possibly longevity benefits, alongside recovery uses.

The accumulated deficit from too little sleep. Some can be repaid with recovery sleep, but chronic debt carries lasting performance and health costs.

The cycle of light, deep, and REM sleep. Deep sleep drives physical repair while REM supports cognitive and emotional processing.

The staged testing (Phase 1–3) a drug passes through, from small safety studies to large efficacy trials. Knowing a peptide’s phase signals how proven it is.

A pharmacy that prepares customized medications. Compounded versions of drugs like semaglutide filled shortage gaps but carry variable oversight.

The regulatory clearance a drug earns after demonstrating safety and efficacy in trials. Most marketed peptides have never gone through it.

Prescribing an approved drug for a use, dose, or group it was not specifically approved for. It is legal and common but shifts responsibility to the prescriber.

How free a product is from contaminants and incorrect sequences. Gray-market peptides often vary widely, posing real safety risks.

Improvement from expectation alone. It is a major reason uncontrolled peptide anecdotes can mislead, and why controlled trials matter.

The gap between animal or lab data (preclinical) and human trials (clinical). Many peptides look impressive preclinically but fail to translate.

A label meaning a substance is sold for laboratory research, not human use. Products bought this way are unregulated for purity and safety.